Treating skin and lung fibrosis in systemic sclerosis: A future filled with promise?

Current Opinion in Pharmacology

Volumn 13, Issue 3, 2013, Pages 455-462

  Antic, Milos ^a   Distler, Jörg H W ^b   Distler, Oliver ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AZATHIOPRINE; BOSENTAN; COLLAGEN TYPE 1; COMPLEMENTARY RNA; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYPROHEPTADINE; IMATINIB; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 6; INTERLEUKIN 6 INHIBITOR; METELIMUMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENICILLAMINE; PLACEBO; PROTEIN INHIBITOR; PROTEIN TYROSINE KINASE; RECOMBINANT HUMAN RELAXIN; RECOMBINANT PROTEIN; RITUXIMAB; SEROTONIN RECEPTOR; TERGURIDE; THYMOCYTE ANTIBODY; TOCILIZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; WNT INHIBITOR; WNT PROTEIN;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B LYMPHOCYTE; CARDIAC GRAFT REJECTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; FIBROSING ALVEOLITIS; HUMAN; HYPERTENSION; IMMUNOPATHOGENESIS; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; LIVER GRAFT REJECTION; LUNG FIBROSIS; LUPUS ERYTHEMATOSUS NEPHRITIS; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; TREATMENT RESPONSE;

ANIMALS; FIBROSIS; HUMANS; PULMONARY FIBROSIS; SCLERODERMA, SYSTEMIC; SKIN;

EID: 84879090366     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2013.05.016     Document Type: Review

References (61)

1. A. Gabrielli, E.V. Avvedimento, and T. Krieg Scleroderma N Engl J Med 360 2009 1989 2003
2. V.D. Steen, and T.A. Medsger Changes in causes of death in systemic sclerosis, 1972-2002 Ann Rheum Dis 66 2007 940 944
3. R.T. Domsic, T. Rodriguez-Reyna, M. Lucas, N. Fertig, and T.A. Medsger Jr. Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma Ann Rheum Dis 70 2011 104 109
4. O. Kowal-Bielecka, R. Landewe, J. Avouac, S. Chwiesko, I. Miniati, and L. Czirjak EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR) Ann Rheum Dis 68 2009 620 628
5. B. Maurer, and O. Distler Emerging targeted therapies in scleroderma lung and skin fibrosis Best Pract Res Clin Rheumatol 25 2011 843 858
6. J.E. Pope, N. Bellamy, J.R. Seibold, M. Baron, M. Ellman, and S. Carette A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma Arthritis Rheum 44 2001 1351 1358
7. F.H. van den Hoogen, A.M. Boerbooms, A.J. Swaak, J.J. Rasker, H.J. van Lier, and L.B. van de Putte Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial Br J Rheumatol 35 1996 364 372
8. R.K. Hoyles, R.W. Ellis, J. Wellsbury, B. Lees, P. Newlands, and N.S. Goh A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma Arthritis Rheum 54 2006 3962 3970
9. D.P. Tashkin, R. Elashoff, P.J. Clements, J. Goldin, M.D. Roth, and D.E. Furst Cyclophosphamide versus placebo in scleroderma lung disease N Engl J Med 354 2006 2655 2666
10. A.C. Allison, and E.M. Eugui Mycophenolate mofetil and its mechanisms of action Immunopharmacology 47 2000 85 118
11. S.I. Nihtyanova, G.M. Brough, C.M. Black, and C.P. Denton Mycophenolate mofetil in diffuse cutaneous systemic sclerosis - a retrospective analysis Rheumatology (Oxford) 46 2007 442 445
12. E.N. Le, F.M. Wigley, A.A. Shah, F. Boin, and L.K. Hummers Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis Ann Rheum Dis 70 2011 1104 1107
13. P.A. Merkel, N.P. Silliman, P.J. Clements, C.P. Denton, D.E. Furst, and M.D. Mayes Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis Arthritis Rheum 64 2012 3420 3429
14. A.E. Postlethwaite, W.K. Wong, P. Clements, S. Chatterjee, B.J. Fessler, and A.H. Kang A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. Oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease Arthritis Rheum 58 2008 1810 1822
15. D. Khanna, P.J. Clements, D.E. Furst, J.H. Korn, M. Ellman, and N. Rothfield Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial Arthritis Rheum 60 2009 1102 1111
16. J.R. Seibold, J.H. Korn, R. Simms, P.J. Clements, L.W. Moreland, and M.D. Mayes Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial Ann Intern Med 132 2000 871 879
17. T.E. King Jr., J. Behr, K.K. Brown, R.M. du Bois, L. Lancaster, and J.A. de Andrade BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis Am J Respir Crit Care Med 177 2008 75 81
18. J.R. Seibold, C.P. Denton, D.E. Furst, L. Guillevin, L.J. Rubin, and A. Wells Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis Arthritis Rheum 62 2010 2101 2108
19. D. Farge, and E. Gluckman Autologous HSCT in systemic sclerosis: a step forward Lancet 378 2011 460 462
20. R.K. Burt, S.J. Shah, K. Dill, T. Grant, M. Gheorghiade, and J. Schroeder Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial Lancet 378 2011 498 506
21. J.M. van Laar, D. Farge, J.K. Sont, K. Naraghi, Z. Marjanovic, and A.J. Schuerwegh The ASTIS trial: autologous stem cell transplantation versus iv pulse cyclophosphamide in poor prognosis systemic sclerosis, first results Ann Rheum Dis 2012 Supplement EULAR. (abstract)
22. J.H.W. Distler, and O. Distler Criteria to select molecular targets for anti-fibrotic therapy Rheumatology 47 2008 v12 v13
23. M.L. Whitfield, D.R. Finlay, J.I. Murray, O.G. Troyanskaya, J.T. Chi, and A. Pergamenschikov Systemic and cell type-specific gene expression patterns in scleroderma skin Proc Natl Acad Sci USA 100 2003 12319 12324
24. N. Asano, M. Fujimoto, N. Yazawa, S. Shirasawa, M. Hasegawa, and H. Okochi B Lymphocyte signaling established by the CD19/CD22 loop regulates autoimmunity in the tight-skin mouse Am J Pathol 165 2004 641 650
25. T. Matsushita, M. Fujimoto, M. Hasegawa, Y. Matsushita, K. Komura, and F. Ogawa BAFF antagonist attenuates the development of skin fibrosis in tight-skin mice J Invest Dermatol 127 2007 2772 2780
26. T. Matsushita, M. Hasegawa, K. Yanaba, M. Kodera, K. Takehara, and S. Sato Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes Arthritis Rheum 54 2006 192 201
27. E. Saito, M. Fujimoto, M. Hasegawa, K. Komura, Y. Hamaguchi, and Y. Kaburagi CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse J Clin Invest 109 2002 1453 1462
28. S. Sato, M. Fujimoto, M. Hasegawa, and K. Takehara Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells Arthritis Rheum 50 2004 1918 1927
29. T.A. Wynn Fibrotic disease and the T(H)1/T(H)2 paradigm Nat Rev Immunol 4 2004 583 594
30. M. Hasegawa, Y. Hamaguchi, K. Yanaba, J.D. Bouaziz, J. Uchida, and M. Fujimoto B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis Am J Pathol 169 2006 954 966
31. S. Bosello, M. De Santis, G. Lama, C. Spano, C. Angelucci, and B. Tolusso B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial Arthritis Res Ther 12 2010 R54
32. D. Daoussis, S.N. Liossis, A.C. Tsamandas, C. Kalogeropoulou, F. Paliogianni, and C. Sirinian Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis Clin Exp Rheumatol 30 Suppl 71 2012 S17 S22
33. V. Smith, Y. Piette, J.T. van Praet, S. Decuman, E. Deschepper, and D. Elewaut Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement J Rheumatol 40 2013 52 57
34. V. Smith, J.T. Van Praet, B. Vandooren, B. Van der Cruyssen, J.M. Naeyaert, and S. Decuman Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study Ann Rheum Dis 69 2010 193 197
35. S. Jordan, J. Distler, B. Maurer, D. Huscher, Y. Allanore, and J.M. van Laar Rituximab improves skin fibrosis and prevents worsening of lung function in patients with systemic sclerosis in the EUSTAR cohort Ann Rheum Dis 2012 (EULAR abstract Supplement)
36. R.M. Gallucci, E.G. Lee, and J.J. Tomasek IL-6 modulates alpha-smooth muscle actin expression in dermal fibroblasts from IL-6-deficient mice J Invest Dermatol 126 2006 561 568
37. T.C. Barnes, M.E. Anderson, and R.J. Moots The many faces of interleukin-6: the role of IL-6 in inflammation, vasculopathy, and fibrosis in systemic sclerosis Int J Rheumatol 2011 2011 721608
38. K. Khan, S. Xu, S. Nihtyanova, E. Derrett-Smith, D. Abraham, and C.P. Denton Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis Ann Rheum Dis 71 2012 1235 1242
39. A. Yoshizaki, K. Yanaba, A. Ogawa, Y. Asano, T. Kadono, and S. Sato Immunization with DNA topoisomerase I and Freund's complete adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling Arthritis Rheum 63 2011 3575 3585
40. M. Elhai, M. Meunier, M. Matucci-Cerinic, B. Maurer, G. Riemekasten, and T. Leturcq Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study Ann Rheum Dis 2012
41. A. Akhmetshina, P. Venalis, C. Dees, N. Busch, J. Zwerina, and G. Schett Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis Arthritis Rheum 60 2009 219 224
42. J.H. Distler, A. Jungel, L.C. Huber, U. Schulze-Horsel, J. Zwerina, and R.E. Gay Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis Arthritis Rheum 56 2007 311 322
43. O. Distler, J. Distler, J. Varga, C.P. Denton, R.A. Lafyatis, and F.M. Wigley A multi-center, open-label, proof of concept study of imatinib mesylate demonstrates no benefit for the treatment of fibrosis in patients with early Diffuse Syst Sclerosis Arthritis Rheum 2010 Supplement ACR abstract
44. D. Khanna, R. Saggar, M.D. Mayes, F. Abtin, P.J. Clements, and P. Maranian A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease Arthritis Rheum 63 2011 3540 3546
45. J. Pope, D. McBain, L. Petrlich, S. Watson, L. Vanderhoek, and F. de Leon Imatinib in active diffuse cutaneous systemic sclerosis: results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center Arthritis Rheum 63 2011 3547 3551
46. S. Prey, K. Ezzedine, A. Doussau, A.S. Grandoulier, D. Barcat, and E. Chatelus Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial Br J Dermatol 167 2012 1138 1144
47. R.F. Spiera, J.K. Gordon, J.N. Mersten, C.M. Magro, M. Mehta, and H.F. Wildman Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial Ann Rheum Dis 70 2011 1003 1009
48. C.E. Daniels, J.A. Lasky, A.H. Limper, K. Mieras, E. Gabor, and D.R. Schroeder Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results Am J Respir Crit Care Med 181 2010 604 610
49. B. Maurer, A. Akhmetshina, R.E. Gay, G. Schett, B.A. Michel, and S. Gay Differences in the activation level of PDGFRβ and c-abl in profibrotic animal models and subsets of human systemic sclerosis may account for the heterogeneous treatment response to tyrosine kinase inhibitors Arthritis Rheum 2012 Supplement ACR abstracts
50. C. Dees, A. Akhmetshina, P. Zerr, N. Reich, K. Palumbo, and A. Horn Platelet-derived serotonin links vascular disease and tissue fibrosis J Exp Med 208 2011 961 972
51. M.R. Ebrahimkhani, F. Oakley, L.B. Murphy, J. Mann, A. Moles, and M.J. Perugorria Stimulating healthy tissue regeneration by targeting the 5-HT(2)B receptor in chronic liver disease Nat Med 17 2011 1668 1673
52. A. Akhmetshina, K. Palumbo, C. Dees, C. Bergmann, P. Venalis, and P. Zerr Activation of canonical Wnt signalling is required for TGF-beta-mediated fibrosis Nat Commun 3 2012 735
53. C. Bergmann, A. Akhmetshina, C. Dees, K. Palumbo, P. Zerr, and C. Beyer Inhibition of glycogen synthase kinase 3beta induces dermal fibrosis by activation of the canonical Wnt pathway Ann Rheum Dis 70 2011 2191 2198
54. C. Beyer, A. Schramm, A. Akhmetshina, C. Dees, T. Kireva, and K. Gelse beta-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis Ann Rheum Dis 71 2012 761 767
55. J. Wei, D. Melichian, K. Komura, M. Hinchcliff, A.P. Lam, and R. Lafyatis Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: a novel mouse model for scleroderma? Arthritis Rheum 63 2011 1707 1717
56. A. Distler, L. Deloch, J. Huang, C. Dees, N.Y. Lin, and K. Palumbo-Zerr Inactivation of tankyrases reduces experimental fibrosis by inhibiting canonical Wnt signalling Ann Rheum Dis 2012
57. M. Konigshoff, M. Kramer, N. Balsara, J. Wilhelm, O.V. Amarie, and A. Jahn WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis J Clin Invest 119 2009 772 787
58. R.J. Akhurst, and A. Hata Targeting the TGFbeta signalling pathway in disease Nat Rev Drug Discov 11 2012 790 811
59. M.C. Ruzek, S. Jha, S. Ledbetter, S.M. Richards, and R.D. Garman A modified model of graft-versus-host-induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease Arthritis Rheum 50 2004 1319 1331
60. B. Santiago, I. Gutierrez-Canas, J. Dotor, G. Palao, J.J. Lasarte, and J. Ruiz Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis J Invest Dermatol 125 2005 450 455
61. C.P. Denton, P.A. Merkel, D.E. Furst, D. Khanna, P. Emery, and V.M. Hsu Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192 Arthritis Rheum 56 2007 323 333